Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 8/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23126444 | 0.90 | FURIN (0.38) | FURINSIRT6SIRT1C3AR1SMN1; SMN2 | |
| SCHEMBL21788282 | 0.90 | FURIN (0.38) | FURINSIRT6SIRT1C3AR1SMN1; SMN2 | |
| SCHEMBL22067692 | 0.90 | FURIN (0.38) | FURINSIRT6SIRT1C3AR1SMN1; SMN2 | |
| SCHEMBL22045351 | 0.88 | FURIN (0.39) | FURINSIRT6SIRT1C3AR1SMN1; SMN2 | |
| SCHEMBL18885738 | 0.88 | FURIN (0.39) | FURINSIRT6SIRT1C3AR1NMT2 | |
| SCHEMBL23220183 | 0.87 | FURIN (0.33) | FURINSIRT6SIRT1C3AR1SMN1; SMN2 | |
| SCHEMBL24420899 | 0.87 | FURIN (0.33) | FURINSIRT6SIRT1C3AR1SMN1; SMN2 | |
| SCHEMBL19198733 | 0.87 | FURIN (0.33) | FURINSIRT6SIRT1C3AR1SMN1; SMN2 | |
| SCHEMBL20803561 | 0.87 | C3AR1 (0.34) | FURINSIRT6SIRT1C3AR1SMN1; SMN2 | |
| SCHEMBL24349699 | 0.87 | SIRT5 (0.36) | FURINSIRT6SIRT1C3AR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
| WO-2021046426-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS TETHERED TO A PD-1 OR CTLA-4 ANTIBODIES | SPEROVIE BIOSCIENCES, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | FURIN 1909/4885SIRT6 2170/4885SIRT1 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.